Cargando…

Effect of the Walking Exercise Program on Cancer-Related Fatigue in Patients with Acute Myeloid Leukemia Undergoing Chemotherapy

BACKGROUND: Cancer-related Fatigue (CRF) is one of the most common complications of acute myeloid leukemia (AML) and its related therapies. It can influence all physical and psychological aspects of the patient’s life. Also, it is believed that exercise can improve CRF in patients with cancer. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gheyasi, Fatemeh, Baraz, Shahram, Malehi, Amal Saki, Ahmadzadeh, Ahmad, Salehi, Reza, Vaismoradi, Mojtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021614/
https://www.ncbi.nlm.nih.gov/pubmed/31244285
http://dx.doi.org/10.31557/APJCP.2019.20.6.1661
Descripción
Sumario:BACKGROUND: Cancer-related Fatigue (CRF) is one of the most common complications of acute myeloid leukemia (AML) and its related therapies. It can influence all physical and psychological aspects of the patient’s life. Also, it is believed that exercise can improve CRF in patients with cancer. OBJECTIVE: This study aimed to investigate the effect of the walking exercise program on CRF in patients with AML undergoing chemotherapy. METHODS: In this quasi-experimental study with a pre- and post-test design, 50 patients with AML undergoing chemotherapy were selected using a convenience sampling method at a teaching hospital in an urban area of Iran. The intervention included daily 30 minutes of planned walking for ten days. Data was collected using a demographic data form and the Brief Fatigue Inventory, which were filled out before the intervention, and on the fifth and tenth days of the intervention. FINDINGS: Statistically significant differences were reported in the reduction of CRF on the fifth day and tenth day of the intervention (p <0.001). CONCLUSIONS: The planned walking intervention can be used as an easy and low-cost method for reducing CRF in patients with leukemia.